MedTrace Logo

Study of Ravulizumab in Pediatric Participants With Primary IgAN

NCT07024563 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-03-17

No results posted yet for this study

Summary

The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.

Conditions

  • IgAN
  • IgAVN
  • Immunoglobulin A Nephropathy
  • Immunoglobulin A Vasculitis Associated Nephritis
  • Henoch-schonlein Purpura Nephritis
  • IgA Vasculitis

Interventions

DRUG

Ravulizumab

Participants will receive Ravulizumab via intravenous (IV) infusion.

Sponsors & Collaborators

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-14
Primary Completion
2028-07-12
Completion
2029-11-27
FDA Drug
Yes

Countries

  • United States
  • China
  • Italy
  • Japan
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07024563 on ClinicalTrials.gov